Výsledky vyhledávání - "M. Mendez Urena"

2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial

Publikováno v: European Journal of Cancer. 51:S371-S372

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9e388ed36c6cb0bb606936cbba3653a
https://doi.org/10.1016/s0959-8049(16)31044-9

Zobrazit plný text záznamu

Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02

Publikováno v: Annals of Oncology. 27:vi178

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e389420b4a833fcf591f837aada73ffe
https://doi.org/10.1093/annonc/mdw370.88

Zobrazit plný text záznamu

Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group

Autor: P. García-Alfonso, G. Pérez-Manga, E Gonzalez-Flores, M. Mendez-Urena, A. Muñoz-Martín, R Quiben-Pereira

Publikováno v: British Journal of Cancer

Background: Combination chemotherapy is standard treatment for metastatic colorectal cancer (MCRC). The aim of this study was to determine the efficacy and safety of capecitabine+irinotecan (2-weekly schedule), as first-line therapy of MCRC. Methods:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f6e9fc434630cd6b835c86d6b58f18
https://pubmed.ncbi.nlm.nih.gov/19738605

Zobrazit plný text záznamu

Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])

Publikováno v: Annals of Oncology. 25:iv168

Aim: The optimal duration and content of first-line therapy in p with mCRC once they have achieved the maximal response remains controversial. This multicenter, randomized, phase II study was aimed to evaluate the efficacy and tolerability of 8 cycle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fbdc91412e4348c0e636194a4d98ce03
https://doi.org/10.1093/annonc/mdu333.3

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání